

of microbial pathogenic organisms and malignant cells; and it is non-hemolytic, namely it has no cytolytic effect on red blood cells or has a cytolytic effect on red blood cells at concentrations which are substantially higher than that in which it manifests said cytolytic activity, said non-hemolytic cytolytic peptide being selected from the group consisting of:

- (A) a cyclic derivative of a peptide having a net positive charge which is greater than +1, and comprising both L-amino acid residues and D-amino acid residues, or comprising one or both of L-amino acid residues and D-amino acid residues, and comprising an α -helix breaker moiety;
- (B) a peptide comprising both L-amino acid residues and D-amino acid residues, having a net positive charge which is greater than +1, and having a sequence of amino acids such that a corresponding amino acid sequence comprising only L-amino acid residues is not found in nature, and cyclic derivatives thereof;
- (C) a complex consisting of a plurality of 2 or more non-hemolytic cytolytic peptides, each peptide having a net positive charge which is greater than +1, and comprising both L-amino acid residues and D-amino acid residues, or comprising one or both of L-amino acid residues and D-amino acid residues and comprising an α -helix breaker moiety, or cyclic derivatives of the foregoing, said peptides being linked together by the use of a linker molecule covalently bound to each of the peptides; and

(D) a random copolymer consisting of a hydrophobic, a positively charged and a D-amino acid.

*Sub
g*
~~8 (Twice-Amended). The peptide according to claim 7,
having the following characteristics:~~

D S
~~(a) it is a non-natural synthetic peptide composed of at least one hydrophobic amino acid and at least one positively charged amino acid, and in which sequence at least one of the amino acid residues is a D-amino acid;~~

~~(b) the peptide has a net positive charge which is greater than +1; and~~

~~(c) the peptide is cytolytic to pathogenic cells but does not cause cytolysis of red blood cells.~~

*Sub
g*
~~16 (Twice-Amended). The complex according to claim 15,
which is composed of 2 or more molecules of the same peptide or of
different peptides, and the linker is:~~

D S
~~(a) a cyclic derivative of a peptide having a net positive charge which is greater than +1, and comprising both L-amino acid residues and D-amino acid residues, or comprising one or both of L-amino acid residues and D-amino acid residues, and comprising an α -helix breaker moiety;~~

~~(b) a peptide comprising both L-amino acid residues and D-amino acid residues, having a net positive charge which is greater than +1, and having a sequence of amino acids such that a corresponding amino acid sequence comprising~~

(c)

only L-amino acid residues is not found in nature, and
cyclic derivatives thereof; or
a commonly used linker.

Cancelled

SAC 91

17 (Thrice-Amended). The complex according to claim 36,
wherein the linked Lys/Leu diastereomers are herein designated 96
and 97:

96. $([D]-L^{3,4,8,10}-K_4L_8C)_5 [D]-L^{3,4,8,10}-K_4L_8$ of the sequence:
 $(\text{Lys-Leu-}\underline{\text{Leu-Leu}}-\text{Lys-Leu-}\underline{\text{Leu}}-\text{Lys-}\underline{\text{Leu}}-\text{Leu-Lys-Cys-NH}_2)_5$
Lys-Leu-Leu-Leu-Lys-Leu-Leu-Lys-Leu-Leu-Lys-NH₂ (SEQ ID NOS: 96
and 23)

97. $([D]-L^{3,4,8,10}-K_5L_7C)_5 [D]-L^{3,4,8,10}-K_4L_9$ of the sequence:
 $(\text{Lys-Leu-}\underline{\text{Leu-Leu}}-\text{Lys-Leu-}\underline{\text{Leu}}-\text{Lys-}\underline{\text{Leu}}-\text{Leu-Lys-Cys-NH}_2)_5$ Lys-Leu-
Leu-Leu-Lys-Leu-Leu-Lys-Leu-Leu-Lys-NH₂ (SEQ ID NOS: 97 and 24).

D 4 SAC 91

20 (Twice-Amended). The non-hemolytic cytolytic random
copolymer according to claim 1(D), consisting of a hydrophobic, a
positively charged and a D-amino acid.

SAC 91

27 (Once-Amended). A composition comprising a
pharmaceutically acceptable carrier and a peptide according to claim
1 in an amount effective to inhibit bacterial growth.

b5

28 (Once-Amended). A composition comprising a
pharmaceutically acceptable carrier and a peptide according to claim
1 in an amount effective to inhibit growth of fungi.

Subj
} 29(Once-Amended). A composition comprising a
pharmaceutically acceptable carrier and a peptide according to claim
1 in an amount effective to inhibit proliferation of cancer cells.

AF 3
D } 31(Once-Amended). A composition comprising a
pharmaceutically acceptable carrier and a peptide according to claim
1 in an amount effective to inhibit a viral activity.

Subj
D } 33(Once-Amended). A composition comprising a
pharmaceutically acceptable carrier and a peptide according to claim
1 in an amount effective to inhibit growth of a protozoan.

Ch 2/10
34(Once-Amended). A mixture consisting of two or more
non-hemolytic cytolytic peptides or cyclic derivatives thereof, each
peptide having a net positive charge which is greater than +1 and
comprising both L-amino acid residues and D-amino acid residues, or
each peptide comprising one or both of L-amino acid residues and D-
amino acid residues and comprising an α -helix breaker moiety.